Published in Genes Cancer on January 01, 2010
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med (2014) 1.04
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci (2015) 0.99
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Induction of Cell Death Mechanisms and Apoptosis by Nanosecond Pulsed Electric Fields (nsPEFs). Cells (2013) 0.91
Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev (2016) 0.90
ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS One (2012) 0.89
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res (2015) 0.87
A novel polysaccharide from Sargassum integerrimum induces apoptosis in A549 cells and prevents angiogensis in vitro and in vivo. Sci Rep (2016) 0.86
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett (2014) 0.86
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol (2016) 0.83
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res (2015) 0.83
Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis. Vasc Cell (2014) 0.82
Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget (2015) 0.82
Concise drug review: pazopanib and axitinib. Oncologist (2012) 0.81
A streamlined search technology for identification of synergistic drug combinations. Sci Rep (2015) 0.81
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. PLoS One (2015) 0.81
Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts. Transl Oncol (2013) 0.81
GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis. Oncotarget (2016) 0.80
STAT3 and mTOR: co-operating to drive HIF and angiogenesis. Oncoscience (2015) 0.80
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer (2014) 0.80
The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors. Mol Cancer (2015) 0.80
Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study. Br J Pharmacol (2015) 0.79
Association of angiogenic factors with prognosis in esophageal cancer. BMC Cancer (2015) 0.79
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget (2015) 0.79
Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol (2013) 0.78
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget (2015) 0.78
Antiangiogenic therapy using endostatin increases the number of ALDH+ lung cancer stem cells by generating intratumor hypoxia. Sci Rep (2016) 0.77
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep (2016) 0.77
An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors. Mol Cancer Ther (2015) 0.76
Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol (2015) 0.76
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecol Oncol (2015) 0.76
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.75
Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells. Cancer Biol Ther (2013) 0.75
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs (2014) 0.75
Differential function and regulation of orphan nuclear receptor TR3 isoforms in endothelial cells. Tumour Biol (2015) 0.75
Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases. PLoS One (2016) 0.75
A Quininib Analogue and Cysteinyl Leukotreine Receptor Antagonist inhibits VEGF-Independent Angiogenesis and Exerts an Additive Anti-angiogenic Response with Bevacizumab. J Biol Chem (2016) 0.75
Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesis. Oncotarget (2015) 0.75
Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. Immunology (2016) 0.75
Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. Oncotarget (2016) 0.75
Tricyclic thiazoles are a new class of angiogenesis inhibitors. Bioorg Med Chem Lett (2013) 0.75
Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs (2015) 0.75
Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol (2017) 0.75
Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers. J Clin Exp Oncol (2017) 0.75
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci (2017) 0.75
Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochem Pharmacol (2017) 0.75
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Cancer-related inflammation. Nature (2008) 34.21
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Cancer metastasis: building a framework. Cell (2006) 19.67
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Tumor angiogenesis. N Engl J Med (2008) 11.30
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell (2006) 9.32
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol (2008) 7.37
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol (2008) 6.42
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 6.32
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 5.96
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell (2009) 5.91
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Common mechanisms of nerve and blood vessel wiring. Nature (2005) 5.46
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer (2002) 5.02
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res (2003) 4.39
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med (2004) 3.63
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J (2003) 3.62
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer (2007) 3.32
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res (2001) 3.21
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res (2007) 2.97
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol (2008) 2.97
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther (2004) 2.97
Hypoxia and cancer. J Mol Med (Berl) (2007) 2.89
Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res (2004) 2.78
Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 2.78
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem (2002) 2.53
Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev (2007) 2.52
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res (2007) 2.49
Calcification of multipotent prostate tumor endothelium. Cancer Cell (2008) 2.49
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 2.40
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
The role of neuropilins in cancer. Mol Cancer Ther (2006) 2.28
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res (2005) 2.16
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer (2008) 2.12
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation (2006) 2.88
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Robust cell polarity is a dynamic state established by coupling transport and GTPase signaling. J Cell Biol (2004) 2.56
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Single-molecule imaging of the H-ras membrane-anchor reveals domains in the cytoplasmic leaflet of the cell membrane. Biophys J (2004) 1.95
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev (2007) 1.86
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron (2011) 1.85
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res (2003) 1.82
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81
Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial. Ann Surg (2011) 1.81
VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med (2003) 1.79
Different time courses for visual perception and action priming. Proc Natl Acad Sci U S A (2003) 1.78
Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 1.77
Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation (2006) 1.76
Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol (2011) 1.75
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest (2006) 1.75
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol (2011) 1.72
Palladium-catalyzed decarboxylative asymmetric allylic alkylation of enol carbonates. J Am Chem Soc (2009) 1.72
Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest (2004) 1.72
Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int (2004) 1.71
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69
Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J (2009) 1.68
Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol (2008) 1.68
Hypoxia-inducible factors 1alpha and 2alpha regulate trophoblast differentiation. Mol Cell Biol (2005) 1.67
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology (2010) 1.64
Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol (2008) 1.62
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol (2002) 1.59
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res (2009) 1.57
Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation (2009) 1.57
Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation (2005) 1.55
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods (2008) 1.55
Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A (2002) 1.52